Beximco Pharmaceuticals (LSE:BXP) FFO


LSE:BXP Beximco Pharmaceuticals PLC LSE:BXP
67 GF Score
Price £0.50
GF Value £0.45
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

LSE:BXP
67GF Score
Beximco Pharmaceuticals PLC LSE:BXP
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of £0.50 is trading 11.1% above its estimated GF Value™ of £0.45. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LSE:BXP:

  • FFO:
  • GF Value™: £0.45 vs. price of £0.50 (11.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
67GF Score

Get the complete analysis for LSE:BXP

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.50
Price
£0.45
GF Value